A retrospective study assessing the real-world treatment patterns of biologic therapies in Crohn's disease (CD) and ulcerative colitis (UC)
Latest Information Update: 06 Jul 2021
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- 06 Jul 2021 New trial record
- 23 May 2021 Results presented at the Digestive Disease Week 2021